Veliparib
Veliparib is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
105 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 14 | 8 | 2 | — | 2 | 26 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 18 | 7 | 1 | — | — | 23 |
| Triple negative breast neoplasms | D064726 | — | — | 6 | 4 | 1 | — | 3 | 14 |
| Lung neoplasms | D008175 | — | C34.90 | 9 | 5 | 2 | — | — | 13 |
| Non-small-cell lung carcinoma | D002289 | — | — | 5 | 5 | 2 | — | — | 9 |
| Glioblastoma | D005909 | EFO_0000515 | — | 4 | 4 | 1 | — | — | 6 |
| Gliosarcoma | D018316 | — | — | 1 | 2 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 20 | 5 | — | — | 4 | 28 |
| Carcinoma | D002277 | — | C80.0 | 15 | 11 | — | — | — | 22 |
| Recurrence | D012008 | — | — | 12 | 4 | — | — | — | 14 |
| Fallopian tube neoplasms | D005185 | — | — | 8 | 3 | — | — | — | 10 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 9 | 3 | — | — | — | 10 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 5 | 3 | — | — | — | 7 |
| Hereditary breast and ovarian cancer syndrome | D061325 | — | — | 4 | 3 | — | — | — | 7 |
| Adenocarcinoma | D000230 | — | — | 4 | 3 | — | — | — | 6 |
| Lymphoma | D008223 | — | C85.9 | 6 | 1 | — | — | — | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 4 | 2 | — | — | — | 5 |
Show 77 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 4 | — | — | — | — | 4 |
| Cystadenocarcinoma | D003536 | — | — | 3 | — | — | — | — | 3 |
| Colonic neoplasms | D003110 | — | C18 | 3 | — | — | — | — | 3 |
| Male breast neoplasms | D018567 | — | — | 3 | — | — | — | — | 3 |
| Endometrioid carcinoma | D018269 | — | — | 2 | — | — | — | — | 2 |
| Mucinous cystadenocarcinoma | D018282 | — | — | 2 | — | — | — | — | 2 |
| Transitional cell carcinoma | D002295 | — | — | 2 | — | — | — | — | 2 |
| Peritoneal neoplasms | D010534 | — | — | 2 | — | — | — | — | 2 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | 1 | 2 |
| Medulloblastoma | D008527 | — | — | 2 | — | — | — | — | 2 |
Show 66 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancytopenia | D010198 | — | D61.81 | — | — | — | — | 1 | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Veliparib |
| INN | veliparib |
| Description | Veliparib is a benzimidazole substituted with a carbamoyl group at C-4 and a (2R)-2-methylpyrrolidin-2-yl moiety at C-2. It is a potent, orally bioavailable PARP inhibitor. It has a role as an EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor. |
| Classification | Small molecule |
| Drug class | poly-ADP-ribose polymerase inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]1(c2nc3c(C(N)=O)cccc3[nH]2)CCCN1 |
Identifiers
| PDB | — |
| CAS-ID | 912444-00-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL506871 |
| ChEBI ID | 62880 |
| PubChem CID | 11960529 |
| DrugBank | DB07232 |
| UNII ID | 01O4K0631N (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,777 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
602 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use